Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

NCT03471351 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
2
Enrollment
INDUSTRY
Sponsor class

Stopped At this point, the current study in HL does not fit into clinical development and regulatory strategy.

Conditions

Interventions

Sponsor

Rhizen Pharmaceuticals SA